FSGS is a clinical disorder characterized by focal scarring of the glomerular capillary tuft, podocyte injury, and nephrotic syndrome. Although idiopathic forms of FSGS predominate, recent insights into the molecular and genetic causes of FSGS have enhanced our understanding of disease pathogenesis. Here, we report a novel missense mutation of the transcriptional regulator Wilms' Tumor 1 (WT1) as the cause of nonsyndromic, autosomal dominant FSGS in two Northern European kindreds from the United States. We performed sequential genome-wide linkage analysis and whole-exome sequencing to evaluate participants from family DUK6524. Subsequently, whole-exome sequencing and direct sequencing were performed on proband DNA from family DUK6975. We identified multiple suggestive loci on chromosomes 6, 11, and 13 in family DUK6524 and identified a segregating missense mutation (R458Q) in WT1 isoform D as the cause of FSGS in this family. The identical mutation was found in family DUK6975. The R458Q mutation was not found in 1600 control chromosomes and was predicted as damaging by in silico simulation. We depleted wt1a in zebrafish embryos and observed glomerular injury and filtration defects, both of which were rescued with wild-type but not mutant human WT1D mRNA. Finally, we explored the subcellular mechanism of the mutation in vitro. WT1 R458Q overexpression significantly downregulated nephrin and synaptopodin expression, promoted apoptosis in HEK293 cells and impaired focal contact formation in podocytes. Taken together, these data suggest that the WT1 R458Q mutation alters the regulation of podocyte homeostasis and causes nonsyndromic FSGS.
in a growing number of genes encoding podocyte proteins have demonstrated that derangements of podocyte structural integrity and function are central features in the development of FSGS. [3] [4] [5] [6] [7] [8] Mutations affecting the transcriptional regulation of podocyte structural proteins have also been identified. In particular, various mutations of the Wilms' Tumor 1 (WT1) gene have been identified as causes of syndromic hereditary FSGS and diffuse mesangial sclerosis (DMS). 9 Mutations in WT1 are typically heterozygous and are usually germline or de novo, although occasional parent-to-child transmission has been reported. 10 WT1 encodes a zinc finger DNA-binding protein that is critical for kidney, urinary tract, and gonadal development. 11 Mutations within the C-terminal zinc finger domains encoded by exons 8 and 9 have been shown to impair the transactivating functions of this podocyte-specific nuclear transcription factor resulting in significant alterations in gene expression of essential slit diaphragm components such as nephrin, podocin, and podocalyxin. [12] [13] [14] [15] [16] [17] Renal phenotypes associated with WT1 mutations include Wilms' tumor as a component of WAGR syndrome (Wilms' tumor, aniridia, genitourinary anomalies, and mental retardation), Denys-Drash syndrome (DDS; Wilms' tumor, male pseudohermaphroditism, and early onset nephrotic syndrome with DMS histology), Frasier syndrome (male pseudohermaphroditism, nephrotic syndrome with FSGS histology, and development of gonadoblastoma), and in some cases nonsyndromic, early onset nephrotic syndrome characterized by DMS histology. 11, 12, [18] [19] [20] [21] To our knowledge, only one case of nonsyndromic, hereditary FSGS due to WT1 mutation, without functional validation, has been reported. 10 Here, we report a novel missense mutation in exon 9 of WT1D (R458Q; transcript ENST00000332351) as a cause of familial FSGS in two multigenerational families of Northern European descent. We demonstrate that depletion of wt1a in zebrafish results in defects in podocyte development coupled with glomerular injury and nephrosis that is rescued by coexpression of wild-type (WT) human WT1D mRNA, but not WT1D R458Q mRNA. The failure of WT1D R458Q to rescue the wt1a morpholino (MO) phenotype suggests a loss-of-function mutation. Given the established role of WT1 in podocyte gene regulation, 13, 14 we overexpressed WT1
WT and WT1 R458Q in human embryonic kidney 293 (HEK293) cells and observed a reduction of nephrin and synaptopodin expression and increased apoptosis in WT1 R458Q -overexpressing cells. Furthermore, we demonstrate WT1-dependent podocyte synaptopodin expression and impaired focal contact formation and wound healing in WT1 R458Q -overexpressing podocytes. In summary, these data provide evidence of a novel mutation within the third zinc finger domain of WT1 (WT1 R458Q ) that causes autosomal dominant FSGS. We also provide novel evidence for the role of WT1 in the transcriptional regulation of synaptopodin gene expression. Finally, we demonstrate the deleterious effects of the WT1 R458Q mutation on cell viability and function in vitro and provide in vivo evidence of the loss-of-function effect of the WT1 R458Q mutation.
RESULTS

Clinical Data and Linkage Analyses
Family DUK6524 is a 5-generation, 88-member kindred from the United States. Eight affected individuals have biopsies diagnostic of or consistent with FSGS ( Figure 1A ). In Figure 1 , B and B', representative periodic acid-Schiff and Masson trichrome-stained sections of kidney biopsy material from the proband demonstrate segmental sclerosis of glomeruli characteristic of FSGS. Both male and female individuals are affected in at least four generations and there is male-to-male transmission consistent with an autosomal dominant pattern of inheritance ( Figure 1A , sex has been deidentified to protect the privacy of individuals). A summary of relevant phenotypic information in six affected individuals is shown in 
Whole-Exome Sequencing
The DNA from the proband was subjected to whole-exome sequencing using the Illumina TruSeq platform. On average, the genomic coverage was 523. After excluding variants with minor allele frequency .1%, 1280 novel variants were identified. The following parameters were used to determine the disease-causing mutation: (1) all variants found in our database of 1600 normal control chromosomes were removed; (2) variants that were in the dbSNP (http://www.ncbi.nlm.nih. gov/projects/SNP/) and 1000 Genome Project (http:// www.1000genomes.org/) databases were removed; (3) all synonymous variants were removed; and (4) all intronic variants were removed except those variants that were in obligatory splice sites, were in promoter regions, or were within 25-50 bases of the intron/exon boundaries. 3, [22] [23] [24] [25] After applying these parameters, there were 187 potential disease-causing variants from the whole-exome data. All of these potential variants were confirmed by Sanger sequencing. The chromosome 11p peak area contains the WT1 gene (Supplemental Figure 1) . A nonsynonymous heterozygous missense change in exon 9 (1327G .A) resulting in an R458Q was identified in WT1D in the proband ( Figure 2C ). An identical change was identified by whole-exome sequencing and confirmed with direct sequencing in a second family with autosomal dominant FSGS (DUK6975) in our cohort ( Figure 2C ). The abbreviated pedigree for family DUK6975 is shown in Supplemental Figure 2 . The R458Q variant (WT1 R458Q ) was the only variant that segregates with disease in the family. The variant is absent from .1600 control chromosomes and is absent from the publicly available 1000 Genome Project data set. This is a sufficient number of controls for a rare Mendelian disease, because a minimum of 350 is needed for 95% power to detect 1% polymorphism frequency. 26 The mutation is conserved in evolution to stickleback ( Figure 2E ). In silico modeling with PolyPhen revealed that the variant is damaging with a deleterious score of 0.947; the variant was also predicted to be damaging by SIFT. [27] [28] [29] Wt1a Deficiency Produces Nephrosis in Zebrafish The zebrafish embryo has a two-nephron, pronephric kidney with high conservation in patterning and podocyte gene expression profiles compared with mammals. To test the hypothesis that the mutation detected in WT1D alters podocyte structure and function during kidney development, we examined the role of wt1a in the zebrafish pronephros. Wt1a is one of two identified zebrafish orthologs to human WT1. Its intracellular functions and localization patterns most closely resemble the characteristics of human WT1D. Wt1a is a 419-amino-acid zinc finger binding protein found to play an essential role in zebrafish nephron development. 30, 31 Zebrafish embryos staged at the eight-cell stage or earlier were microinjected with a splice-blocking MO against wt1a (wt1a MO) to suppress the splicing of wt1a mRNA. 30 In parallel, fluoresceinlabeled 70-kD dextran was microinjected into the common cardinal vein to fill the vascular system of zebrafish embryos; the clearance rate of dextran was used as an established functional expression of filtration efficiency in the zebrafish pronephros. 32 At 6 days postfertilization (dpf), we observed pericardial and yolk sac edema in morphant zebrafish larvae relative to control samples ( Figure 3, A and B) . Rapid dextran clearance was also seen in morphant embryos and the dextran clearance rate was correlated with the presence and severity of edema ( Figure 3 , E and F). A high dextran clearance rate leads to significantly less fluorescein in the vascular network of the trunk ( Figure 3 , J and J') and retina ( Figure 3N ) in morphant relative to control larvae ( Figure 3 , I, I' , and M). Coinjection of human WT1D
WT -whose protein product shows 71% identity with zebrafish wt1a at the amino acid level and whose function, expression, and localization most closely resemble that of wt1a-ameliorated the observed phenotypes (Figure 3 , C, G, K, K' , and O), suggesting these results are gene specific and support the role of WT1D in renal filtration. 30 To quantify the severity of pronephric filtration leakage, we plotted the percentage of zebrafish larvae with edema and defects in dextran clearance for each condition ( Figure 3Q ). Relative to WT1D WT , WT1D
R458Q was unable to rescue the wt1a morphant phenotypes (Figure 3 , D, H, L, L' , and P), suggesting that the R458Q mutation is pathogenic.
To analyze the effects of WT1D R458Q mRNA on pronephric kidney development, we next investigated podocyte histology and foot process development by hematoxylin and eosin and transmission electron microscopy. At 6 dpf, we observed a reduction in the size of the kidney in morphant embryos relative to WT samples ( 
J-L)
. These results support a pathogenic role of the R458Q allele in the development of nonsyndromic FSGS.
WT1
R458Q Alters the Regulation of Podocyte Genes To examine the effects of WT1 R458Q on the regulation of key podocyte genes, we used real-time PCR on RNA isolates from WT1
WT or WT1 R458Q -expressing HEK293 cells. HEK293 cells were selected as the model system for these studies given their amenability to transfection relative to podocytes and because the endogenous expression of multiple slit diaphragm proteins has been previously demonstrated in the line. 14, [33] [34] [35] In Figure 5A , we demonstrate that the relative expression of WT1
WT and WT1
R458Q
in transfected HEK293 cells is similar. Because WT1 is recognized as a key regulator of nephrin expression, 14 we evaluated the effect of WT1 R458Q expression on mRNA expression of various podocyte slit diaphragm components, including nephrin (NPHS1), TRPC6, synaptopodin (SYNPO), and CD2-associated protein (CD2AP) in WT1 R458Q and WT1
WT -overexpressing HEK293 cells ( Figure 5 , B and C). There was no significant difference in TRPC6 or CD2AP mRNA expression in WT1 R458Q and WT1
WT -expressing cells ( Figure 5 , B and C). By contrast, the expression of NPHS1 and SYNPO was significantly downregulated by 1.6-fold (P=0.01) and 2-fold (P=0.001) respectively ( Figure 5 , B and C). These findings support the prior work of Guo et al. and Wagner et al., which established WT1 as a regulator of NPHS1 gene expression, 14 and additionally suggest for the first time that WT1 is a transcriptional regulator of synaptopodin gene activation.
Apoptosis in WT1
R458Q -Overexpressing HEK293 Cells Because of the established role of nephrin in podocyte cell survival signaling, 36 R458Q -overexpression promotes cellular apoptosis and may do so via a mechanism involving downregulation of nephrin. 36 Targeted WT1 Gene Knockdown Attenuates Synaptopodin Expression and Basal Podocyte Motility WT1 is a known transcriptional activator of nephrin expression in podocytes. 37 To evaluate the role of WT1 in podocyte synaptopodin gene expression, we next performed WT1 gene knockdown (KD) in differentiated immortalized human podocytes. WT1 gene KD markedly reduced Synaptopodin expression in podocytes ( Figure 6A, n=2) . In addition, WT1 KD significantly impaired basal podocyte motility by almost 30% ( Figure 6 , B and C, n=4, P=0.004). These results demonstrate that WT1 is a transcriptional activator of synaptopodin gene expression and may thereby participate in the regulation of podocyte motility.
Overexpression of WT1D
R458Q Impairs Focal Contact Assembly in Podocytes Synaptopodin is known to play an important role in the assembly and maintenance of focal contacts in podocytes through inhibition of Smurf1-mediated polyubiquitination of RhoA. 38 Because we established that WT1 R458Q overexpression results in decreased synaptopodin expression, we sought to determine the effect of WT1 R458Q overexpression on focal contact assembly in podocytes. We confirmed the expression of the integral focal contact protein vasodilator-stimulated phosphoprotein in podocytes under growth-permissive and growth-restrictive conditions ( Figure 7A ). In WT1 R458Q -overexpressing podocytes, the presence of vasodilator-stimulated phosphoprotein in focal contacts is impaired relative to WT1
WT or turbo green fluorescent protein (tGFP)-overexpressing cells (Figure 7, n=2) . These findings suggest that WT1 R458Q may exert its deleterious effects on podocyte focal contact assembly through the disruption of Synaptopodin expression.
DISCUSSION
Despite the identification of causal mutations in FSGS, an understanding of the genetic mechanisms in the majority of cases remains elusive. Common to all reports of FSGS is the dysregulation of podocyte homeostasis, suggesting that mechanisms that disrupt this process are germane to the pathogenesis of glomerular damage during the onset and progression of disease. Using linkage analysis and whole-exome sequencing, we identified a novel mutation in WT1 that causes a nonsyndromic form of autosomal dominant FSGS. Our in vivo and in vitro assays demonstrate that wt1 regulates glomerular morphogenesis and that the mutant R458Q WT1 allele alters the formation, patterning, and gene expression of podocytes. Given our findings, we recommend the inclusion of WT1 in future diagnostic platforms that screen for potential causes of autosomal dominant FSGS.
Mutations of WT1 have been associated with syndromic disorders of the renal and urogenital systems such as DDS. DDS results from missense mutations within exons 8 or 9 and produces a classic triad of pseudohermaphroditism, DMS nephropathy, and a predisposition to the development of Wilms' tumor. 39, 40 Notably, the DDS WT1 R394W mutation within the third zinc finger binding domain impairs WT1-DNA interaction and deleteriously affects the expression of various podocyte genes including nephrin, podocin, and podocalyxin. [13] [14] [15] [16] [17] 
R394T mutation. 16 Specifically, these authors used gene expression profiling in isolated glomerular preparations from WT1
R394T
-expressing mice to identify SceI and Sulf1, two podocyte expressed genes whose downregulation in WT1
R394T mutants was strongly associated with the development of the DDS phenotype. 16 Collectively, these findings demonstrate the functional significance of mutations affecting the third zinc finger domain of WT1 and illustrate the diversity of processes served by WT1 in the developing renal and urogenital systems.
Our findings reveal that expression of WT1 R458Q in HEK cells and differentiated human podocytes produced a number of deleterious effects, including decreased nephrin and synaptopodin mRNA expression, increased apoptosis, and impaired focal contact assembly. Given these findings, we posit that the underlying mechanism may involve podocyte apoptosis secondary to dysregulation of nephrin-associated survival signaling and podocyte matrix attachment secondary to impaired synaptopodin expression. In support of these hypotheses, Huber et al. demonstrated that in HEK293 cells, nephrin and CD2AP interact with the regulatory p85 subunit of PI-3K and that overexpression of nephrin induces AKT-mediated phosphorylation and deactivation of the proapoptotic signaling molecule Bad. 36 Guo et al. demonstrated that WT1 is a key regulator of nephrin expression in HEK293 cells. 14 It is possible that the increased apoptosis observed in WT1 R458Q -expressing HEK cells may be due to disruption of its interaction with p53. Maheswaran et al. reported a stabilizing, antiapoptotic interaction with p53, which inhibited apoptosis in Saos-2 osteosarcoma cells. 41 Although this interaction was mapped to the first and second zinc finger regions of WT1, it is possible that the R458Q mutation promotes destabilization and that this interaction leads to increased apoptosis. 41 Alternatively, we do acknowledge that because WT1 is known to be involved in proapoptotic signaling, 42 the increased apoptosis in observed in HEK cells may represent a deleterious gain-of-function effect of the R458Q mutation.
Synaptopodin maintains cytoskeletal integrity, as demonstrated by the work of Yanagida-Asanuma et al. in which they demonstrated an essential role for synaptopodin in protection against proteinuria via the inhibition of podocyte filopodia formation. 43 In addition, Asanuma et al. demonstrated that synaptopodin plays an essential role in the formation of focal contacts via the inhibition of Smurf1-mediated polyubiquitination of RhoA. 38 Specifically, targeted synaptopodin gene knockdown in podocytes promoted derangement of focal contact assembly, podocyte dysmotility, and enhanced RhoA polyubiquitination. Therefore, we recommend that WT1 be included as a cause of nonsyndromic FSGS in the development of future diagnostic platforms.
CONCISE METHODS
Case Ascertainment
Institutional review board approval was obtained from Duke University Medical Center (Durham, NC). Families with FSGS were identified through the International Collaborative Group on Familial FSGS. Inclusion criteria and determination of affection status are as previously reported. 44 Briefly, inclusion in this analysis required at least one individual with biopsy-proven FSGS and a second family member with FSGS and/or ESKD. Clinical evaluation of these kindreds included a full family history, physical examination, urinalysis with qualitative or quantitative proteinuria, and serum creatinine assay when appropriate. Renal pathology reports and slides were reviewed when available for affected individuals. Individuals were classified as affected, probably affected, or unaffected as follows.
Affected
Individuals were affected if they required dialysis, had undergone renal transplantation, had 2+ to 4+ proteinuria by qualitative urinalysis $500 mg/24 h on quantitative urinalysis, or had a renal biopsy demonstrating FSGS without evidence of other systemic diseases known to cause FSGS or chronic renal failure.
Probably Affected
Participants were classified as probably affected if they had trace to 1+ proteinuria on qualitative urinalysis. These individuals were categorized as unknown in the linkage analysis. 
Unaffected
Individuals who had no detectable proteinuria on qualitative urinalysis and were unrelated married-in spouses were classified as unaffected. We excluded mutation in known autosomal dominant FSGS genes (ACTN4, TRPC6, and INF2) in all of the affected individuals.
Genotyping and Linkage Analyses
DNA Isolation and Genotyping
Genomic DNAwas isolated from peripheral blood through the Center for Human Genetics at the Duke University Medical Center using PureGene. Fluorescence genotyping was carried out as described 44 with 135 prelabeled Hex and Fam multiplex primer sets, comprising 351 microsatellite markers, which provided an average spacing of 10 cM across the genome. A Hitachi FMBIOII was used for detection; data were processed using Bio Image and databased using Pedigene. 44 
Linkage Analyses
Two-point and multipoint LOD scores were calculated using VITESSE. 45 A LOD score of $3.0 is considered significant evidence for linkage and #22.0 is significant evidence for exclusion of linkage to the region. Values in between these are inconclusive and additional data are needed before a conclusion can be reached. For two-point LOD scores $3.0, a 1-LOD-unit-down support interval was calculated as an approximation to a 95% confidence interval. 46 Marker allele frequencies were calculated using approximately 100 chromosomes from unrelated, ethnically matched controls. The marker allele/control frequencies did not differ substantially from those calculated from the unrelated spouses in the family. In addition, a conservative low-penetrance "affected-only" analysis was performed to ensure that results obtained were not due to asymptomatic individuals who were nonpenetrant carriers of the FSGS gene. Map distances WT -overexpressing cells.
for the marker loci were obtained from published data (http://www.gdb. org/).
Haplotype Analyses
Haplotype analysis was performed as previously described 47 to identify critical recombination events. Briefly, haplotype analysis was carried out via visual inspection, assigning the most likely linkage phase by minimizing the number of recombinants within a pedigree. A candidate interval was considered excluded when two affected individuals within a pedigree inherited different haplotypes from a common affected ancestor. Finally, genetic heterogeneity was evaluated by using the admixture test as implemented in HOMOG. 46 Sequencing
Whole-Exome Sequencing
Whole-exome sequencing was performed on the proband using standard protocols. We used the Agilent All Exon 50MB kit and sequenced to 78.33 coverage using one lane of a Hisses 2000 sequencer. Reads were aligned to the Human Reference genome (HG 18) using the BWA software. Any homozygous variants with ,103 coverage were also Sanger sequenced to eliminate false negative results. Single nucleotide variants were called using SAM tools. The variants were annotated to Ensembl (http://useast.ensembl.org/index. html) 50_36l using SequenceVariantAnalyzer and were analyzed using the ATAV software.
Sanger Sequencing
All of the potential disease-causing variants that were identified genome wide were confirmed by Sanger sequencing. Briefly, both strands of all of the variants were sequenced using exon flanking primers. In addition, both strands of all the coding exons of WT1 were sequenced in 100 families with FSGS using the same method. All sequences were analyzed with Sequencher software (Gene Codes Corp., Ann Arbor, MI).
In Silico Prediction of the Effect of Amino Acid Substitution
The R458Q variant in WT1 was entered into PolyPhen 2 software to examine the predicted damaging effect of the amino acid substitution to the function of WT1. The HumVar-trained version was used, which is optimal for Mendelian disorders because it distinguishes mutations with drastic effects from all the remaining human variation, including abundant mildly deleterious alleles. PolyPhen-2 calculates a naïve Bayes posterior probability that any mutation is damaging and this is represented with a score ranging from 0 to 1. A mutation was also appraised qualitatively, as benign, possibly damaging, or probably damaging based on the model's false positive rate. 27 HEK293 Culture and mRNA Extraction HEK293 cultures were established as previously described. 3 Total RNA was manually extracted from HEK293 cells using an RNeasy Mini kit (Qiagen, Valencia, CA). Subsequently, 0.5 mg of total RNA was reverse transcribed into cDNA utilizing the RT system (Promega Corporation, Madison, WI) with oligo(dT) primers, according to the manufacturer's protocol. The cDNA was diluted 2.5-fold for the realtime PCR reaction. Quantification of mRNA by real-time PCR was performed using the ABI 7900 HT system (Applied Biosystems, Foster City, CA). PCR reactions for b-Actin and WT1, TRPC6, NPHS2, NPHS1, SYNPO, and WT1 were performed in a final volume of 10 ml, consisting of 2 ml cDNA, 2.5 ml RNAse and DNAse free water, 0.5 ml of 203 TaqMan Gene Expression Assays (Table 1) , and 5 ml of TaqMan 23 PCR Master Mix (both Applied Biosystems). The target DNA was amplified during 40 cycles of 50°C for 2 minutes, 95°C for 10 minutes, 15 seconds, and 60°C for 1 minute. Each individual experiment was performed three times, in duplicate. Relative expression of the target genes was analyzed by normalizing to the housekeeping gene b-Actin.
Immunoblotting
After plasmid transfection, HEK293 cells cultures were washed once with ice-cold PBS. Cells were then harvested in loading buffer (Cell Signaling Technologies, Boston, MA) supplemented with 1 mM calyculin A (EMD Millipore, Billerica, MA) and protease inhibitor cocktail, 1:400 dilution (Sigma-Aldrich). Whole cell extracts were then passed through a 1-ml syringe (BD Biosciences, San Jose, CA) 10 times. Cell lysates were then subjected to SDS-PAGE using NuPAGE 10% Bis-Tris precast gels (Invitrogen) followed by transfer to 0.2-mM pore size polyvinylidene difluoride membrane (EMD Millipore). Membranes were blocked with 1-hour incubation in 5% milk in PBS. Protein immunoblotting was then performed using a mouse monoclonal anti-WT1 antibody at a dilution of 1:1000 (LifeSpan Biosciences, Seattle, WA) and mouse monoclonal b-actin antibody at a concentration of 1:3000 (Sigma-Aldrich).
Membranes were then washed once with PBS and incubated for 1 hour with horseradish peroxidase-conjugated goat anti-mouse polyclonal secondary antibody at 1:10,000 dilution (Invitrogen). Immunolabeled proteins were detected using a chemiluminescence detection system (Pierce Biotechnology, Rockford, IL) on Kodak Biomax film (VWR Scientific, Radnor, PA).
Conditionally Immortalized Human Podocyte Culture and Reagents
Conditionally immortalized human podocytes were cultured under growth-permissive conditions at 33°C in RPMI 1640 medium (Gibco, Gaithersburg, MD) supplemented with 10% FBS (Gibco), 1:100 penicillin-streptomycin (Invitrogen, Grand Island, NY), and 5% 1003 insulin-transferrin-selenium supplement (Invitrogen). Podocyte differentiation was induced by transfer of cultures to growth-restrictive conditions at 37°C.
Plasmid Construction and Lipid-Based Plasmid Transfection
Plasmids expressing tGFP-tagged human WT1 WT were purchased from OriGene (Rockville, MD). Site-directed mutagenesis was performed by standard PCR-based methods and plasmid purification was performed using the Qiagen Plasmid Midi Kit. Lipid-based plasmid transfections were performed per manufacturer's protocols using the Lipofectamine LTX with Plus Reagent system (Invitrogen , and 24 hours after transfection, cells were harvested and cell lysates were prepared for immunoblotting or mRNA extraction as previously described.
Immunofluorescence
Conditionally immortalized human podocytes and HEK293 cells were cultured on collagen I-coated coverslips (BD Biosciences) and treated as indicated. Cells were then fixed with 4% paraformaldehyde in PBS (Sigma-Aldrich). Cells were then washed twice with ice-cold PBS before permeabilization with 0.1% Triton X-100 in PBS. Cells were then washed with ice-cold PBS twice and blocked with buffer containing 5% goat serum before incubation with mouse monoclonal WT1 antibody (LifeSpan Biosciences, Seattle, WA), and mouse monoclonal nephrin antibody (Novus Biologicals, Littleton, CO) overnight at 4°C. Cells were then washed with ice-cold PBS and secondary Alexa Flora 488 antibody was applied (Invitrogen) at a concentration of 1:1000 for 1 hour at room temperature. Cells were then washed four times with PBS at room temperature before addition of 49,6-diamidino-2-phenylindole stain at a concentration of 1:10,000 diluted in PBS. Immunofluorescence imaging was performed using a Carl Zeiss AxioImager and the MetaMorph Bioimaging Software.
Apoptosis Assays
HEK293 cells were plated in 12-well tissue culture clusters (Evergreen Scientific, Los Angeles, CA) and transfected with the green fluorescent protein-expressing construct pEGP-N1 (0.4 mg per well; Clontech Laboratories, Palo Alto, CA) and either wild-type WT1 or mutant WT1 (1.2 mg per well; Upstate) using Lipofectamine (Invitrogen, Carlsbad, CA) according to the manufacturer's directions. After transfection, HEK293 cells were harvested and apoptosis was detected via the presence of Annexin V staining using the BD Pharmingen Annexin V PE kit (San Diego, CA) according to the manufacturer's directions. Quantitation of the apoptotic cells was performed by flow cytometric analysis at the Duke Comprehensive Cancer facility by gating on green fluorescent protein-positive cells. For the Annexin V studies, apoptotic podocytes were differentiated from necrotic cells by counting cells that stained with 7-amino-actinomycin D. Results are expressed as the mean6SEM for three experiments with statistical significance established at P,0.05.
Scratch Wound Healing Assay and Reagents
Immortalized podocyte cultures were differentiated under growthrestrictive conditions for 10 days. Cells were then washed once with RPMI 1640 media supplemented with 10% FBS (transfection media). Next, cells were transfected with control or WT1 small interfering RNAs using RNAiMax transfection reagent. Cells were then returned to growth-restrictive conditions for 3 days before scratch wound creation. Scratch wounds were applied using a 1000-ml plastic pipette tip. Cell monolayers were then washed once with transfection media after wound creation. Podocytes were then imaged using an EVOS microscope at time 0 hours immediately after wound creation. Cells were then returned to growth-restrictive conditions for 24 hours before final images of wound healing were obtained. Data are expressed as the "percent wound healing," which represents the percent difference in wound area after 24 hours.
In Vivo Analyses Zebrafish Stocks and Injections
Zebrafish (EK) were grown and mated at 28.5°C, and embryos were kept and handled in embryo medium as previously described. 48 MO was injected in fertilized eggs in the one-to eight-cell stage using a Picospritzer injection device. The following MO against wt1a was designed and ordered from GeneTools (Philomath, OR): 59-AAAG-TAGTTCCTCACCTTGATTCCT-39. MO injections were carried out with a concentration of 10 ng/nl, with an injection volume of 0.5 nl in 0.1% phenol red). Embryos were monitored for the development of phenotype until 6 dpf. Phenotype was scored relative to the presence of yolk edema and dextran clearance defect.
Eye Assays
Two types of eye assays were performed to assess proteinuria. At 2.5 days after MO injection, remaining chorions were manually removed from all embryos. For one group, cardinal vein injections were performed as described by Hentschel et al. 32 Briefly, 4.6 nl FITClabeled 70-kD dextran (Molecular Probes, Eugene, OR) was injected into the common cardinal vein. For this injection, zebrafish were anesthetized in a 0.2 mg/ml Tricaine (ethyl-m-aminobenzoate methanesulfonate, 1% Na 2 HPO 4 , pH 7.0; Sigma-Aldrich) and positioned on their backs in a 1% agarose injection mold. After the injection, fish were returned to embryo medium, where they quickly regained motility. Fish were anesthetized with Tricaine and sequential images of live fish were generated using a Nikon AZ100 microscope connected to a Nikon DS-Qi1 camera, and images were taken with fixed exposure times and gain using the Nikon NIS-Elements software package.
Statistical Analyses
All data are represented as the mean6SEM. Group differences were assessed by the t test. Statistical significance was established at P,0.05.
